Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population

Authors :: K. van der Weide
T. van der Straaten
Kirsten M. Pondman
Jan P.A.M. Bogers
Jan N. M. Commandeur
J. van der Weide
Harriet M. Loovers
Dan Cohen
Ellen Langemeijer
AIMMS
Molecular and Computational Toxicology
Source :: Pharmacogenomics Journal, 17(5), 471-478, Pharmacogenomics Journal. Nature Publishing Group, Van der Weide, K, Loovers, H, Pondman, K, Bogers, J, van der Straaten, T, Langemeijer, E V, Cohen, D, Commandeur, J N M & van der Weide, J 2016, ' Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. ', Pharmacogenomics Journal . https://doi.org/10.1038/tpj.2016.32
Publication Year :: 2014
Abstract: Prescription of clozapine is complicated by the occurrence of clozapine-induced reduction of neutrophils. The aim of this study was to identify genetic risk factors in a population of 310 Dutch patients treated with clozapine, including 38 patients developing neutropenia and 31 patients developing agranulocytosis. NQO2 1541AA (NRH quinone oxidoreductase 2; protects cells against oxidative metabolites) was present at a higher frequency in agranulocytosis patients compared with control (23% versus 7%, P=0.03), as was ABCB1 (ABC-transporter-B1; drug efflux transporter) 3435TT (32% versus 20%, P=0.05). In patients developing neutropenia, ABCB1 3435TT and homozygosity for GSTT1

Tools